IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Skurkovich & Skurkovich

Appl. No.: 08/771,831

Filed: December 23, 1996

For: Treatment of Autoimmune Diseases,

INCLUDING AIDS

Art Unit: 1816

Examiner: unknown

Atty. Docket: ABC-0001CIP



Information Disclosure Statement

Assistant Commissioner for Patents Washington, D.C. 2023 l

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each of the following documents is provided: 3 US patents (A1-C1), 1 PCT publication (R1), and 73 Publications (AA-CU).

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that an exhaustive search has been made, or that there does not exist information more material to the examination of the

Applicants: Skurkovich & Skurkovich Appl. No. 08/771,831 present patent application. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will review art of record in all 35 U.S.C. § 120 priority documents. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No certification or fee is required. It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to Deposit Account No. 13-2489. Respectfully submitted, Erdyn H Me Coxattal Evelyn H. McConathy

Date: July 21, 1997

11723 Quay Road Oakton, VA 22124 (703) 716-5240

C/WP61/ADV-BIO/ABC-0001 CIPATRANSLTR IDS

Attorney for Applicants Registration No. 35,279